SAN CARLOS, CALIFORNIA and TORONTO, ONTARIO — Natera, a leading innovator in prenatal genetic testing, and LifeLabs Medical Laboratory Services (LifeLabs), a Canadian company with over 50 years’ experience in laboratory testing and management, today announced a distribution partnership for Natera’s non-invasive prenatal screening test, Panorama(TM). Panorama was launched in March 2013 for the detection […]
BILLERICA, Mass — RainDance Technologies, Inc., the Digital Biology™ Company, announced a publication demonstrating the use of the company’s digital PCR technology for detecting mutations in circulating tumor DNA directly from blood samples. The paper, co-authored by a consortium of research clinicians in France and RainDance scientists, highlights the significant value unlocked by the company’s […]
SEATTLE — NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Prosigna™ Breast Cancer Prognostic Gene Signature Assay. Based on the PAM50 gene signature, Prosigna is the company’s […]
LEXINGTON, Mass. — T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the initiation of the direcT2 clinical trial of T2Candida®, T2 Bio’s flagship product for the rapid and sensitive identification of five species of Candida. The direcT2 trial will provide data to support a regulatory submission for T2Candida. T2Candida uses […]
Beverly, MA and Boulder, CO — Enzymatics, Inc., a leading producer of reagents, kits, and assays, today announced it has acquired Boulder-based ArcherDx, Inc., a developer of innovative, NGS-based kits and software solutions for use in investigating cancer treatment. The deal consists of cash, equity and potential milestones worth up to $50 million. Jason Myers, […]
SAN DIEGO, Sept. — Trovagene, Inc. (NASDAQ: TROV), a developer of molecular diagnostics for cancer monitoring, today announced that the Company has entered into a clinical collaboration agreement with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using Trovagene’s proprietary cell-free DNA assays. The study is designed to demonstrate that […]
EXTON, Pa.— ThingWorx™ today announced that Biocartis, an innovative molecular diagnostics company, has selected ThingWorx as the Machine-to-Machine (M2M) application platform to power its next-generation remote service offering. Biocartis intends to use the ThingWorx application platform to provide remote instrument connectivity and innovative M2M applications, extending its molecular diagnostics solution with high-value remote service and […]
BARCELONA, Spain – At the 12th International Congress of Inborn Errors of Metabolism (www.iciem2013.com), Bruker announces another milestone in the cost-effective use of NMR (nuclear magnetic resonance) spectroscopy screening as a clinical research tool for metabolic screening and small molecule in vitro diagnostics (IVD) research and validation. The novel Inborn Errors of Metabolism (IEM) screening […]
Lausanne (Switzerland) / Mechelen (Belgium) – Biocartis, a molecular diagnostics company, announces today that Ulrik Cordes has joined the company as Chief Commercial Officer (CCO). Ulrik Cordes is an executive with 18+ years of experience in marketing and sales in the med-tech, pharma and biotech industry, of which the past 10 years in top level […]
Qlucore has been awarded funding of €0.6 million over a three year period by the European Commission’s 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of mathematical and statistical algorithms focusing on integrating data from multiple analytical platforms focusing on integrating genetic and proteomic data with […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
